Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: A cost-effectiveness analysis

Justin S. Yu, Rashad Carlton, Neetu Agashivala, Tarek Hassan, Charles C. Wykoff

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: A cost-effectiveness analysis'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemistry

Social Sciences